{"entity":{"id":"zanzalintinib","kind":"drug","name":"Zanzalintinib","aka":[],"tldr":"Zanzalintinib is an experimental small-molecule drug from Exelixis in phase 3 trials for neuroendocrine tumours, head and neck squamous cell carcinoma and renal cell carcinoma, aimed at VEGF / VEGFR and MET.","summary":"Zanzalintinib (XL092) is a small-molecule drug developed by Exelixis and Merck Sharp & Dohme. Its targets are VEGF / VEGFR and MET (the sponsor names MET/VEGFR/AXL/MER). The sponsor states: Exelixis describes zanzalintinib as a next-generation tyrosine kinase inhibitor (TKI) targeting MET, VEGFR, AXL and MER receptors. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06943755 (Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumours), NCT06082167 (Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma) and NCT07227402 (A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)), in neuroendocrine tumours, head and neck squamous cell carcinoma and renal cell carcinoma. The largest, NCT07227402, plans to enrol 904 participants with primary completion expected 2032-02-27. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Zanzalintinib","url":"https://clinicaltrials.gov/search?intr=XL092"},{"label":"Sponsor pipeline page","url":"https://www.exelixis.com/pipeline/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["neuroendocrine","head-and-neck","rcc"],"sections":[],"technologies":[],"targets":["vegf","met"],"drugs":[],"companies":["exelixis","merck"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06943755","nct06082167","nct07227402","nct07489495","nct05425940","nct07049926"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"XL092","modality":"small molecule","mechanism":"Exelixis describes zanzalintinib as a next-generation tyrosine kinase inhibitor (TKI) targeting MET, VEGFR, AXL and MER receptors.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/zanzalintinib/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"target":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"company":[{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}],"trial":[{"id":"nct07489495","kind":"trial","name":"A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)","route":"/trials/nct07489495/"},{"id":"nct07227402","kind":"trial","name":"A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)","route":"/trials/nct07227402/"},{"id":"nct07620574","kind":"trial","name":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study","route":"/trials/nct07620574/"},{"id":"nct07677579","kind":"trial","name":"NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer","route":"/trials/nct07677579/"},{"id":"nct05425940","kind":"trial","name":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer","route":"/trials/nct05425940/"},{"id":"nct06082167","kind":"trial","name":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06082167/"},{"id":"nct07049926","kind":"trial","name":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (","route":"/trials/nct07049926/"},{"id":"nct07750158","kind":"trial","name":"Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease","route":"/trials/nct07750158/"},{"id":"nct06943755","kind":"trial","name":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors","route":"/trials/nct06943755/"}]}}